1. Synergistic anticancer activity of the targeted drugs imatinib, regorafenib, and gefitinib with the RAD51 inhibitor IBR2. (December 2016) Authors: Ferguson, P.; Vincent, M.; Koropatnick, J. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S121 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗